This is the second part of a series of posts on biomarkers.  For the first one, click here… The pharma industry, investors and company founders are now realising the potential of biomarkers to transform drug discovery and development.  Worldwide, major bio industry conferences are Read more...

Attending a life science conference recently, I was suddenly struck by the dramatic change in perception that has occurred regarding the relevance of biomarkers to drug discovery and development. It was heartening to see, not least because I was part of the industrialisation of genomics research Read more...

Yesterday’s publication of PriceWaterhouseCooper’s evaluation of the biotechnology industry provides some sobering reading.  Amongst the doom and gloom there’s promise and some pointers for where this industry’s service providers should look for securing and growing Read more...

New technologies and services that lack a coherent marketing strategy can languish for years before they produce a decent revenue stream.   Take microdosing services for pharmaceutical development.   When this concept was launched commercially nearly 10 years ago it was positioned as a way to Read more...